Davida Roth News Today

Tamibarotene plus azacitidine and venetoclax has received FDA fast track designation for newly diagnosed, unfit, RARA-overexpressed AML.

Syros Pharmaceuticals , a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the United States Food...

Tamibarotene is an oral selective retinoic acid receptor alpha (RARα) agonist. The FDA has granted Fast Track designation to tamibarotene in combination with azacitidine and venetoclax for the treatment of newly diagnosed AML with RARA overexpression.

The addition of the oral, selective RARα agonist tamibarotene to venetoclax and azacitidine produced higher responses rates compared with venetoclax and azacitidine alone in response-evaluable patients with newly diagnosed, RARA-overexpressed acute myeloid leukemia.

-- New data support further evaluation of SY-5609 for PDAC and HR+ breast cancer and demonstrate significant potential for SY-5609 in a wide range of tumor types and combinations -- -- Consistent... | May 25, 2023

25.05.2023 - Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced new clinical data from the Phase 1/1b clinical trial evaluating ... Seite 1

12.12.2022 - Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced a peer-reviewed publication of results from its completed biomarker-directed Phase 2 trial of tamibarotene in ... Seite 1

The Food and Drug Administration has granted Orphan Drug designation to SY-5609 for the treatment of pancreatic cancer.

The US Food and Drug Administration has granted orphan drug designation to SY-5609 for the treatment of pancreatic cancer.

The Food and Drug Administration has granted Orphan Drug designation to SY-5609 for the treatment of pancreatic cancer.